Cowen & Co. Maintains a Buy Rating on X4 Pharmaceuticals Inc (XFOR)

By Jason Carr

In a report released today, Marc Frahm from Cowen & Co. maintained a Buy rating on X4 Pharmaceuticals Inc (XFORResearch Report). The company’s shares closed last Monday at $11.83.

According to TipRanks.com, Frahm ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.9% and a 37.7% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Magenta Therapeutics Inc, and Applied Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for X4 Pharmaceuticals Inc.

See today’s analyst top recommended stocks >>

Based on X4 Pharmaceuticals Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $13.38 million. In comparison, last year the company had a GAAP net loss of $10.9 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003.